Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced that positive preliminary data from two ongoing clinical trials of sitravatinib in non-small cell ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Mirati Therapeutics (MRTX) Trades at High, Up 150%September 15, 2017 10:54 AM Mirati Therapeutics (MRTX) PT Raised to $9 at Leerink PartnersSeptember 15, 2017 8:04 AM Mirati Therapeutics Presents Positive Preliminary Data From On-Going Clinical Trials Of Sitravatinib In Non-Small Cell Lung CancerSeptember 14, 2017 4:33 PM Mirati Therapeutics (MRTX) Halted, News PendingSeptember 14, 2017 4:27 PM